Table 2.
Main characteristics of the followed patients
| Variable | Category | Colorectal cancer (n=2097) | Breast cancer (n=1685) |
Prostate cancer (n=1055) |
| Age, mean (±SD) | 66.98 (±10.85) | 56.5 (±12.6) | 65.86 (±7.38) | |
| Gender | Female | 763 (36.39%) | 1685 (100%) | – |
| Male | 1334 (63.61%) | – | 1055 (100%) | |
| Postmenopausal | Yes | – | 1095 (65.0%) | – |
| No | – | 589 (35.0%) | – | |
| Missing | – | 1 (0.1%) | – | |
| Histology (specific types in each tumour) |
Adenocarcinoma: 1882 (89.75%) | Ductal: 1276 (75.7%) | Adenocarcinoma (acinar): 1053 (99.91%) | |
| Mucinous adenocarcinoma: 125 (5.96%) | Lobular :110 (6.5%) | Others: 2 (0.09%) | ||
| Signet ring cells adenocarcinoma: 12 (0.57%) | Paget disease: 19 (1.1%) | – | ||
| Others: 4 (0.19%) | Others: 280 (16.6%) | – | ||
| Unknown: 74 (3.53%) | – | – | ||
| Tumour size | T0 | 98 (4.67%) | 23 (1.4%) | – |
| T1 | 125 (5.96%) | 861 (51.1%) | 227 (21.52%) | |
| T2 | 283 (13.49%) | 424 (25.2%) | 521 (49.38%) | |
| T3 | 1172 (55.89%) | 73 (4.3%) | 98 (9.29%) | |
| T4 | 319 (15.21%) | 39 (2.3%) | 8 (0.76%) | |
| Tis | – | 109 (6.5%) | – | |
| Missing | 100 (4.77%) | 156 (9.3%) | 196 (18.58%) | |
| Not evaluable | – | – | 5 (0.47%) | |
| Node infiltration | N0 | 1193 (56.89%) | 877 (52.0%) | 271 (25.69%) |
| N1 | 515 (24.56%) | 441 (26.2%) | 9 (0.85%) | |
| N2 | 286 (13.64%) | 186 (11.0%) | – | |
| N3 | – | 5 (0.3%) | – | |
| Missing | 103 (4.91%) | 176 (10.4%) | 224 (21.23%) | |
| Not evaluable | – | – | 551 (52.23%) | |
| Metastasis | No | 1721 (82.07%) | 1376 (81.7%) | 532 (50.43%) |
| Yes | 330 (15.74%) | 41 (2.4%) | 17 (1.61%) | |
| Missing | 46 (2.19%) | 268 (15.9%) | 215 (20.38%) | |
| Not evaluable | – | – | 291 (27.58%) | |
| Clinical stage | 0 | 77 (3.67%) | – | – |
| I | 338 (16.12%) | 702 (41.7%) | 367 (34.79%) | |
| II | 673 (32.09%) | 479 (28.4%) | 496 (47.01%) | |
| III | 569 (27.13%) | 179 (10.6%) | 132 (12.51%) | |
| IV | 330 (15.74%) | 41 (2.4%) | 17 (1.61%) | |
| Missing | 110 (5.25%) | 284 (16.9%) | 43 (4.08%) | |